Evaluation of antibody–chemokine fusion proteins for tumor-targeting applications

The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer

(2013) Teresa Hemmerle et al.   INTERNATIONAL JOURNAL OF CANCER

Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia

(2013) K. L. Gutbrodt et al.   Science Translational Medicine

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Antibody–cytokine fusion proteins

(2012) Roland E. Kontermann   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts

(2012) M. Moschetta et al.   CANCER RESEARCH

Immunocytokines: a novel class of potent armed antibodies

(2012) Nadine Pasche et al.   DRUG DISCOVERY TODAY

Overview of the mechanisms regulating chemokine activity and availability

(2012) Anneleen Mortier et al.   IMMUNOLOGY LETTERS

Chemokine-based immunotherapy: delivery systems and combination therapies

(2012) Elham Mohit et al.   Immunotherapy

A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data

(2012) T. Hemmerle et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

(2011) M. Steiner et al.   CLINICAL CANCER RESEARCH

Antibody Conjugate Therapeutics: Challenges and Potential

(2011) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

(2011) Kathrin Schwager et al.   HUMAN REPRODUCTION

Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors

(2011) Melissa G Lechner et al.   Immunotherapy

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

(2011) Katharina Frey et al.   Integrative Biology

Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7

(2011) Nadine Pasche et al.   JOURNAL OF BIOTECHNOLOGY

A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin

(2011) Alessandra Villa et al.   mAbs

What's fueling the biotech engine—2010 to 2011

(2011) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy

(2010) Ping Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Chemokines

(2010) Steven M. Dubinett et al.   CANCER JOURNAL

Effect of posttranslational processing on the in vitro and in vivo activity of chemokines

(2010) Anneleen Mortier et al.   EXPERIMENTAL CELL RESEARCH

LIM and SH3 Protein -1 Modulates CXCR2-Mediated Cell Migration

(2010) Dayanidhi Raman et al.   PLoS One

Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12

(2010) Roberto Sommavilla et al.   PROTEIN ENGINEERING DESIGN & SELECTION

VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis

(2009) N. F. Neel et al.   JOURNAL OF CELL SCIENCE

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

(2009) Christoph Schliemann et al.   LEUKEMIA RESEARCH

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

(2009) Kathrin Schwager et al.   ARTHRITIS RESEARCH & THERAPY

TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model

(2008) Hiroyuki Inoue et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo

(2008) Alessandra Villa et al.   INTERNATIONAL JOURNAL OF CANCER